Description General description A 3-amino substituted pyrazoloquinoxaline compound that acts as a selective inhibitor of cyclin-dependent kinases 1 and 5 (Cdks; IC50 = 0.6 µM and 0.4 µM for Cdk1/cyclin B and Cdk5/p25, respectively). Also shown to inhibit GSK-3β with (IC50 = 1 µM). Does not inhibit Cdc25 phosphatase activity (IC50 > 10 µM). A selective inhibitor of cyclin-dependent kinases 1 and 5 (Cdk1/Cdk5) (IC50 = 600 nM for Cdk1/cyclin B and 400 nM for Cdk5/p25). Also shown to inhibit glycogen synthase kinase-3β (GSK-3β) (IC50 = 1 µM). Does not inhibit Cdc25 phosphatase activity (IC50 > 10 µM). Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: no Primary Target Cdk1/cyclin B, Cdk5/p25 Product does not compete with ATP. Reversible: no Target IC50: 0.6 µM and 0.4 µM for Cdk1/cyclin B and Cdk5/p25, respectively Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Ortega, M.A., et al. 2002. Bioorg. Med. Chem.10, 2177.